Margin of about 11 trillion 64 billion won…listed on KOSPI on the 5th of next month
[서울파이낸스 남궁영진 기자] Prestige Biopharma, a pharmaceutical company specializing in antibody drug development, announced on the 26th that it has recorded a competition rate of 237:1 by conducting public offerings for general investors for two days from the previous day.
According to Samsung Securities, the listing organizer of Prestige Biopharma, this general offer was targeted at 3.288328 shares, which is 20% of the total offer volume. As a result, a total of 727.58470 shares were received, and the margin amounted to about 11.64 trillion won.
The company’s total number of publicly offered shares is 15,341640 shares, and the public offering price is 32,000 won, which is expected to raise about 490.9 billion won. The public offering funds will be actively used for R&D and facility investment, as well as for entering the global market. It will be listed on the stock market (KOSPI) next month.
For Prestige Biopharma, the initial filing date of the stock report was before December last year, so the procedure was carried out in the conventional method of allocating public offering stocks according to the number of weeks subscribed.
Park So-yeon, CEO of Prestige Bio Pharma, said, “We will do our best to fulfill our obligations as a KOSPI-listed company through transparent and responsible management activities even after listing and become a global antibody drug development pharmaceutical company.”
Prestige Biopharma is a Singapore-based company that develops eight biosimilars and two new antibody drugs. Herceptin biosimilar (HD201), which is at the earliest stage of development, has successfully completed phase 3 clinical trials required for product approval, and is currently preparing for marketing approval in Europe.
In addition, the new pancreatic cancer antibody drug (PBP1510) is about to start phase 1/2a clinical trials in Korea and Europe with the aim of acquiring the status of an innovative new drug (first-in-class).
Copyright © Seoul Finance Unauthorized reproduction and redistribution prohibited